IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-01772997.html
   My bibliography  Save this paper

Current process and future path for health economic assessment of pharmaceuticals in France

Author

Listed:
  • Mondher Toumi

    (Laboratoire de Santé Publique - Université de la Méditerranée - Aix-Marseille 2)

  • Cécile Rémuzat

    (Creativ-Ceutical)

  • Emna El Hammi

    (Evidenz)

  • Aurélie Millier

    (Creativ-Ceutical)

  • Samuel Aballéa

    (Creativ-Ceutical)

  • Christos Chouaid

    (BCR - Biomécanique cellulaire et respiratoire - INSERM - Institut National de la Santé et de la Recherche Médicale - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12 - CNRS - Centre National de la Recherche Scientifique)

  • Bruno Falissard

    (UMR_S 669 - Troubles du comportement alimentaire de l'adolescent - UP11 - Université Paris-Sud - Paris 11 - UPD5 - Université Paris Descartes - Paris 5 - INSERM - Institut National de la Santé et de la Recherche Médicale)

Abstract

The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee (Commission Evaluation Economique et de Santé Publique, or CEESP) in the Social Security Code as a specialised committee affiliated with the Haute Autorité de Santé in charge of providing recommendations and health economic opinions. This article provides an in-depth description of the CEESP's structure and working methods, and analyses the impact of health economic assessment on market access of drugs in France. It also points out the areas of uncertainty and the conflicting rules following the introduction of the health economic assessment in France. The authors also provide their personal opinion on the likely future of health economic assessment of drugs in France, including the possible merge of the CEESP and the Transparency Committee, the implementation of a French threshold, and the extension of health economic assessment to a larger number of products.

Suggested Citation

  • Mondher Toumi & Cécile Rémuzat & Emna El Hammi & Aurélie Millier & Samuel Aballéa & Christos Chouaid & Bruno Falissard, 2015. "Current process and future path for health economic assessment of pharmaceuticals in France," Post-Print hal-01772997, HAL.
    • Handle: RePEc:hal:journl:hal-01772997
    DOI: 10.3402/jmahp.v3.27902
    Note: View the original document on HAL open archive server: https://amu.hal.science/hal-01772997
    as

    Download full text from publisher

    File URL: https://amu.hal.science/hal-01772997/document
    Download Restriction: no
    File URL: https://libkey.io/10.3402/jmahp.v3.27902?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Alexei Botchkarev, 2016. "Toward Development of a New Health Economic Evaluation Definition," Papers 1608.01891, arXiv.org.
    2. Fernando Antoñanzas & Robert Terkola & Paul M. Overton & Natalie Shalet & Maarten Postma, 2017. "Defining and Measuring the Affordability of New Medicines: A Systematic Review," PharmacoEconomics, Springer, vol. 35(8), pages 777-791, August.
    3. Alexei Botchkarev, 2016. "Essential notion of the health economic evaluation: Definition," Economic Analysis Working Papers (2002-2010). Atlantic Review of Economics (2011-2016), Colexio de Economistas de A Coruña, Spain and Fundación Una Galicia Moderna, vol. 2, pages 1-1, December.
    4. Alexei BOTCHKAREV, 2016. "Toward Development of a New Health Economic Evaluation Definition," Journal of Economics Bibliography, KSP Journals, vol. 3(4), pages 590-601, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-01772997. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.